© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Heparanase Gene Silencing, Tumor Invasiveness, Angiogenesis, and Metastasis
Affiliations of authors: Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (EE, ME, EZ, TP); Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel (IV)
Correspondence to: Israel Vlodavsky, PhD, Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, 31096, Israel (e-mail: vlodavsk{at}cc.huji.ac.il)
Background: Heparanase is an endoglycosidase that degrades heparan sulfate, the main polysaccharide constituent of the extracellular matrix and basement membrane. Expression of the heparanase gene is associated with the invasive, angiogenic, and metastatic potential of diverse malignant tumors and cell lines. We used gene-silencing strategies to evaluate the role of heparanase in malignancy and to explore the therapeutic potential of its specific targeting. Methods: We designed plasmid vectors to express hammerhead ribozymes or small interfering RNAs (siRNAs) directed against the human or mouse heparanase mRNAs. Human breast carcinoma (MDA-MB-435) and mouse lymphoma (Eb) and melanoma (B16-BL6) tumor cell lines, which have naturally high levels of endogenous heparanase or have been genetically engineered to overexpress heparanase, were transfected with anti-heparanase ribozyme or siRNA. Semiquantitative reverse transcription–polymerase chain reaction (RT-PCR) and measurements of enzymatic activity were used to confirm the efficient silencing of heparanase gene expression. Cells transfected with the anti-heparanase ribozyme and siRNA vectors were tested for invasiveness in vitro and metastatic dissemination in animal models of experimental and spontaneous metastasis. Results: Compared with cells transfected with control constructs, cells transfected with the anti-heparanase ribozyme or siRNA vectors had profoundly reduced invasion and adhesion in vitro, regardless of cell type, and expressed less heparanase. In vivo, tumors produced by cells transfected with the anti-heparanase ribozyme and siRNA vectors were less vascularized and less metastatic than tumors produced by cells transfected with the control vectors. Mice injected with cells transfected with the anti-heparanase ribozyme and siRNA vectors lived longer than mice injected with control cells. Conclusions: The association of reduced levels of heparanase and altered tumorigenic properties in cells with anti-heparanase ribozyme- or siRNA-mediated gene-silencing vectors suggests that heparanase is important in cancer progression. Heparanase gene silencing has potential use as a target for anticancer drug development.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Involvement of Heparanase in Tumor Metastases: A New Target in Cancer Therapy?
- Douglas D. Boyd and Motowo Nakajima
J Natl Cancer Inst 2004 96: 1194-1195.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  G. Abboud-Jarrous, R. Atzmon, T. Peretz, C. Palermo, B. B. Gadea, J. A. Joyce, and I. Vlodavsky Cathepsin L Is Responsible for Processing and Activation of Proheparanase through Multiple Cleavages of a Linker Segment J. Biol. Chem., June 27, 2008; 283(26): 18167 - 18176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Koyama, H. Naruo, Y. Yoshitomi, S. Munesue, S. Kiyono, Y. Kusano, K. Hashimoto, T. Yokoi, H. Nakanishi, S. Shimizu, et al. Matrix Metalloproteinase-9 Associated with Heparan Sulphate Chains of GPI-Anchored Cell Surface Proteoglycans Mediates Motility of Murine Colon Adenocarcinoma Cells J. Biochem., May 1, 2008; 143(5): 581 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Wood and M. D. Hulett Cell Surface-expressed Cation-independent Mannose 6-Phosphate Receptor (CD222) Binds Enzymatically Active Heparanase Independently of Mannose 6-Phosphate to Promote Extracellular Matrix Degradation J. Biol. Chem., February 15, 2008; 283(7): 4165 - 4176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cohen-Mazor, S. Sela, R. Mazor, N. Ilan, I. Vlodavsky, A. L. Rops, J. van der Vlag, H. I. Cohen, and B. Kristal Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients? Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H651 - H658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Lerner, L. Baraz, E. Pikarsky, A. Meirovitz, E. Edovitsky, T. Peretz, I. Vlodavsky, and M. Elkin Function of Heparanase in Prostate Tumorigenesis: Potential for Therapy Clin. Cancer Res., February 1, 2008; 14(3): 668 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gingis-Velitski, R. Ishai-Michaeli, I. Vlodavsky, and N. Ilan Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing FASEB J, December 1, 2007; 21(14): 3986 - 3993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hostettler, A. Naggi, G. Torri, R. Ishai-Michaeli, B. Casu, I. Vlodavsky, and L. Borsig P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins FASEB J, November 1, 2007; 21(13): 3562 - 3572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cohen, B. Maly, I. Simon, A. Meirovitz, E. Pikarsky, E. Zcharia, T. Peretz, I. Vlodavsky, and M. Elkin Tamoxifen Induces Heparanase Expression in Estrogen Receptor Positive Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4069 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xu, J. Ding, G. Rao, J. Shen, R. A. Prinz, N. Rana, and W.P. Dmowski Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium Hum. Reprod., April 1, 2007; 22(4): 927 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xu, G. Rao, R. M. Quiros, A. W. Kim, H.-Q. Miao, G. J. Brunn, J. L. Platt, P. Gattuso, and R. A. Prinz In Vivo and in Vitro Degradation of Heparan Sulfate (HS) Proteoglycans by HPR1 in Pancreatic Adenocarcinomas: LOSS OF CELL SURFACE HS SUPPRESSES FIBROBLAST GROWTH FACTOR 2-MEDIATED CELL SIGNALING AND PROLIFERATION J. Biol. Chem., January 26, 2007; 282(4): 2363 - 2373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gotte and G. W. Yip Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective Cancer Res., November 1, 2006; 66(21): 10233 - 10237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Basche, D. L. Gustafson, S. N. Holden, C. L. O'Bryant, L. Gore, S. Witta, M. K. Schultz, M. Morrow, A. Levin, B. R. Creese, et al. A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors. Clin. Cancer Res., September 15, 2006; 12(18): 5471 - 5480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhao, H. Liu, Y. Chen, X. Xin, J. Li, Y. Hou, Z. Zhang, X. Zhang, C. Xie, M. Geng, et al. Oligomannurarate Sulfate, a Novel Heparanase Inhibitor Simultaneously Targeting Basic Fibroblast Growth Factor, Combats Tumor Angiogenesis and Metastasis. Cancer Res., September 1, 2006; 66(17): 8779 - 8787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Yip, M. Smollich, and M. Gotte Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther., September 1, 2006; 5(9): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shafat, I. Vlodavsky, and N. Ilan Characterization of Mechanisms Involved in Secretion of Active Heparanase J. Biol. Chem., August 18, 2006; 281(33): 23804 - 23811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Edovitsky, I. Lerner, E. Zcharia, T. Peretz, I. Vlodavsky, and M. Elkin Role of endothelial heparanase in delayed-type hypersensitivity Blood, May 1, 2006; 107(9): 3609 - 3616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Negrini, O. Tenstad, A. Passi, and H. Wiig Differential degradation of matrix proteoglycans and edema development in rabbit lung Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L470 - L477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zetser, Y. Bashenko, E. Edovitsky, F. Levy-Adam, I. Vlodavsky, and N. Ilan Heparanase Induces Vascular Endothelial Growth Factor Expression: Correlation with p38 Phosphorylation Levels and Src Activation Cancer Res., February 1, 2006; 66(3): 1455 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. de Mestre, S. Rao, J. R. Hornby, T. Soe-Htwe, L. M. Khachigian, and M. D. Hulett Early Growth Response Gene 1 (EGR1) Regulates Heparanase Gene Transcription in Tumor Cells J. Biol. Chem., October 21, 2005; 280(42): 35136 - 35147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Nasser, E. Nevo, I. Shafat, N. Ilan, I. Vlodavsky, and A. Avivi Adaptive evolution of heparanase in hypoxia-tolerant Spalax: Gene cloning and identification of a unique splice variant PNAS, October 18, 2005; 102(42): 15161 - 15166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Levy-Adam, G. Abboud-Jarrous, M. Guerrini, D. Beccati, I. Vlodavsky, and N. Ilan Identification and Characterization of Heparin/Heparan Sulfate Binding Domains of the Endoglycosidase Heparanase J. Biol. Chem., May 27, 2005; 280(21): 20457 - 20466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Naggi, B. Casu, M. Perez, G. Torri, G. Cassinelli, S. Penco, C. Pisano, G. Giannini, R. Ishai-Michaeli, and I. Vlodavsky Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting J. Biol. Chem., April 1, 2005; 280(13): 12103 - 12113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Boyd and M. Nakajima Involvement of Heparanase in Tumor Metastases: A New Target in Cancer Therapy? J Natl Cancer Inst, August 18, 2004; 96(16): 1194 - 1195. [Full Text] [PDF]
|
|